2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
27
Lung Neoplasms
7
Neoplasm Metastasis
4
Recurrence
3
Non Small Cell Lung Cancer Metastatic
3
Neuroblastoma
3
Neoplasms
3
Meningeal Carcinomatosis
2
Brain Neoplasms
2
Advanced Non-Small Cell Lung Cancer
2
ALK Positive Non-small Cell Lung Cancer
2
Thrombocytosis
1
Sexual Dysfunction, Physiological
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Non-Small Cell Lung Cancer ALK-positive
1
Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
1
Neurofibromatosis 1
1
Neoadjuvant Non-Small Cell Lung Cancer
1
NSCLC
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Anaplastic
1
Lung Diseases
1
Leukemia, Myelomonocytic, Chronic
1
Interventions
Cyclophosphamide
65
Peripheral Blood Stem Cell Transplantation
37
fludarabine phosphate
36
Doxorubicin
31
Etoposide
30
Vincristine
29
Whole-Body Irradiation
28
Rituximab
26
Prednisone
26
Brentuximab Vedotin
26
Mycophenolic Acid
25
Filgrastim
22
Cyclosporine
22
Methotrexate
20
Busulfan
19
Cytarabine
18
Radiotherapy
17
Antilymphocyte Serum
16
Tacrolimus
15
Melphalan
15
Carboplatin
14
Ifosfamide
13
Bortezomib
13
Methylprednisolone
12
Gemcitabine
11
Flow Cytometry
10
Lenalidomide
9
Dexamethasone
9
romidepsin
8
Vorinostat
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Large-Cell, Anaplastic
×
lorlatinib
×
Clear all
NCT03505554
2023-08-07
CRU3
University of Milano Bicocca
Phase 2
Unknown
12 enrolled